Signal Explorer

Fda Aligned Interim Data Positive Expanded Access Program Active Publication Positive Enrollment Ahead Of Schedule

Clinical Trial Result Indication Expansion Clinical Hold Lead Asset Progress Combination Therapy Mentioned

Clinical Hold Active

Regulatory Designation Only Clinical Trial Result Lead Asset Progress Clinical Hold Indication Expansion

Fast Track Granted Orphan Status Granted Fast Track Designation Received Breakthrough Therapy Granted Publication Positive Interim Data Positive Protocol Amended Rmat Designation Received

Orphan Drug Designation Clinical Hold Active

Auditor Appointment Ratification Classified Board Director Election Activist Board Representation Demand

Lead Asset Progress Indication Expansion Clinical Hold

Protocol Amended Gene Therapy Aav

Nasdaq Minimum Bid Price Delisting Notice Nyse Listing Disclosure

Litigation Defense Assertion Material Weakness In Internal Controls Disclosed Net Loss Reported Director Continuity Stated Capital Raising Uncertainty Disclosed Equity Plan Share Reserve Disclosure Personnel Cost Decrease Disclosure Restrictive Debt Covenants Disclosure Nasdaq Minimum Bid Price Delisting Notice Fast Track Designation Received Patent Family Portfolio Disclosure Fast Track Granted

Regulatory Designation Only

Trial Endpoint Missed Orphan Drug Designation

Change Of Control Definition Net Loss Reported Arbitrator Selection Procedure Liquidity Position Snapshot Disclosed Nasdaq Minimum Bid Price Delisting Notice Equity Plan Share Reserve Disclosure Director Officer Indemnification Provision Cause For Termination Defined Fast Track Designation Received Stock Option Intrinsic Value Disclosure Fast Track Granted Stock Option Grant Disclosed Other Income Expense Disclosure Survival Of Representations Warranties Clause

Regulatory Designation Only

Liquidity Position Snapshot Disclosed Protocol Amended Net Loss Reported Forward Looking Statement Definition Personnel Cost Decrease Disclosure Enrollment Ahead Of Schedule Expanded Access Program Active

Indication Expansion Lead Asset Progress Clinical Hold Clinical Trial Result

Clinical Hold Active Crl Received

Lead Asset Progress Indication Expansion Management Exodus

Merger Proxy Statement Disclosure Nasdaq Minimum Bid Price Delisting Notice Stockholder Engagement Disclosure Activist Board Representation Demand Board Diversity Policy Disclosed Fast Track Designation Received

Board Diversity Policy Disclosed Forward Looking Statement Definition Merger Proxy Statement Disclosure Board Committee Composition Disclosure Stockholder Engagement Disclosure Executive Transition Gratitude Statement Fda Aligned

Indication Expansion Lead Asset Progress Management Exodus

Net Loss Reported Revenue Decline Explanation Liquidity Position Snapshot Disclosed Personnel Cost Decrease Disclosure Administrative Efficiency Gene Therapy Aav Operating Margin Declining Forward Looking Statement Definition

Lead Asset Progress Indication Expansion

Trial Endpoint Missed

Demand Softening

Nasdaq Minimum Bid Price Delisting Notice

Nasdaq Minimum Bid Price Delisting Notice Nyse Listing Disclosure

Executive Severance Change Of Control

Executive Educational Background Disclosure

Management Exodus Indication Expansion Lead Asset Progress